Cost Estimate of Immune-Related Adverse Reactions Associated with Innovative Treatments of Metastatic Melanoma.

Clinical Drug Investigation
F S MenniniMichele Del Vecchio

Abstract

Immuno-oncology therapies represent a new treatment opportunity for patients affected by metastatic melanoma. The purpose of this study was to estimate the costs of immune-related adverse events (irAEs) associated with the new anti-PD1 immuno-oncology therapies, with the anti-CTLA-4 immuno-oncology therapy and with the combined therapy (CTLA4 + anti-PD1) in patients affected by metastatic melanoma. A probabilistic cost-of-illness (COI) model was developed to estimate the management costs of grade ≥ 3 adverse events associated with the new anti-PD1 therapies (pembrolizumab and nivolumab), the anti-CTLA-4 therapy (ipilimumab) and the combined therapy CTLA4 + anti-PD1 (nivolumab + ipilimumab) for the treatment of patients with metastatic melanoma from the National Health Service (NHS) perspective in Italy. Identification of the epidemiological and cost parameters was carried out through a systematic literature review (SLR). Univariate and probabilistic sensitivity analyses were performed to account for uncertainty and variation in the model results. The model estimated a cost associated with the management of grade ≥ 3 immune-related adverse events in patients with metastatic melanoma equal to €176.2 (95% CI 63.5-335.0) for anti-C...Continue Reading

References

Jun 8, 2010·The New England Journal of Medicine·F Stephen HodiWalter J Urba
Jun 7, 2011·The New England Journal of Medicine·Caroline RobertJedd D Wolchok
Oct 9, 2013·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Michele Del VecchioMichele Maio
Apr 9, 2014·Journal of Experimental & Clinical Cancer Research : CR·Vanna Chiarion SileniPaola Queirolo
Nov 18, 2014·The New England Journal of Medicine·Caroline RobertPaolo A Ascierto
Apr 22, 2015·The New England Journal of Medicine·Caroline RobertUNKNOWN KEYNOTE-006 investigators
May 3, 2015·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Ayfer KarlitepeCigir Biray Avci
Jun 2, 2015·The New England Journal of Medicine·James LarkinJedd D Wolchok
Jan 2, 2016·The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care·Elizabeth WehlerBeth Barber
Feb 15, 2016·Cancer Treatment Reviews·Lavinia SpainJames Larkin
Apr 29, 2016·Cancer Research and Treatment : Official Journal of Korean Cancer Association·Minkyu JungSang Joon Shin
May 10, 2016·Clinical Therapeutics·Jon ZugazagoitiaLuis Paz-Ares

❮ Previous
Next ❯

Citations

Jul 17, 2020·Journal of Immunology Research·Massimo RalliAntonio Greco
Sep 21, 2020·Annals of Surgical Oncology·Hayley StandageDale Han
Jan 15, 2022·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·Manuel David Gil-SierraMarina Sánchez-Hidalgo

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Vaccines

Cancer vaccines are vaccines that either treat existing cancer or prevent development of a cancer.